Nichi-Iko Delays US Infliximab Amid Coronavirus Outbreak
As Japanese Company Trains Focus On Bevacizumab
Nichi-Iko maintains it is still on course to be one of the very few players to offer an ‘interchangeable’ biosimilar in the US, with its rival to Janssen’s Remicade. The Japanese company has revealed its latest schedule as it also reported full-year financial results.
You may also be interested in...
Teva has announced a major strategic shift in Japan, with its Teva Takeda Pharma joint venture striking a deal to divest the majority of its traditional generics business to Nichi-Iko so that it can focus instead on complex generics and specialty products.
Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.
Sandoz’ operation in Egypt has banded together with the Egyptian Cancer Society to introduce the firm’s biosimilar to Roche’s Rituxan/MabThera, three years after Hikma in-licensed a rituximab biosimilar from Celltrion.